Приказ основних података о документу
Integrated biopharmaceutical approach in pharmaceutical development and drug characterization: General concept and application
Integrisani biofarmaceutski pristup u razvoju i karakterizaciji lekova: opšti koncept i primena
dc.creator | Cvijić, Sandra | |
dc.creator | Ibrić, Svetlana | |
dc.creator | Parojčić, Jelena | |
dc.date.accessioned | 2021-03-03T12:28:39Z | |
dc.date.available | 2021-03-03T12:28:39Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 0367-598X | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/3790 | |
dc.description.abstract | The importance of biopharmaceutical considerations in pharmaceutical development and drug characterization has been well recognized both by pharmaceutical industry and regulatory authorities as a tool to establish predictive relationships between drug product quality attributes (in vitro data) and its clinical performance (in vivo data). In the present paper, contemporary biopharmaceutics toolkit including in vivo predictive dissolution testing, Biopharmaceutics Classification System, physiologically based pharmacokinetic and biopharmaceutics modeling and simulation, in vitro-in vivo correlation and biowaiver, are reviewed with regards to relevant general principles and applicability. The recently introduced innovative strategy for patient-centric drug development using an integrated systems approach grounded in fundamental biopharmaceutics concepts, clinical insights and therapeutic drug delivery targets, described as Biopharmaceutics Risk Assessment Roadmap (BioRAM) is also presented. Further development in the field will benefit from joint efforts and exchange of knowledge and experiences between pharmaceutical industry and regulatory authorities for the common goal to accelerate development of effective and safe drug products designed in accordance with patients’ needs and expectations. | |
dc.description.abstract | Značaj biofarmaceutskih razmatranja u razvoju i karakterizaciji lekova s ciljem uspostavljanja korelacije i mogućnosti predviđanja odnosa između in vitropodataka, odnosno karakteristika kvaliteta leka i njegovog in vivoponašanja/kliničkog učinka, prepoznata je kako od strane farmaceutske industrije, tako i od strane odgovarajućih regulatornih tela. U radu je dat pregled savremenih biofarmaceutskih alata,uključujući prediktivno ispitivanje brzine rastvaranja lekovite supstance iz farmaceutskog oblika leka, Biofarmaceutski sistem klasifikacije, fiziološki zasnovano farmakokinetičko i biofarmaceutsko modelovanje i simulacije, in vitro-in vivokorelaciju i mogućnost izostavljanja in vivostudija bioekvivalencije (engl. biowaiver) iz aspekta opštih principa i mogućnosti primene u razvoju i karakterizaciji lekova.Predstavljena je i nedavno osmišljena inovativna strategija za razvoj leka usmerena ka pacijentu, uz primenu integrisanog sistemskog pristupa zasnovanog na osnovnim biofarmaceutskim konceptima, uvidu u kliničku situaciju i definisanim terapijskim ciljevima označena kao Plan aktivnosti za procenu biofarmaceutskog rizika (engl. Biopharmaceutics Risk Assessment Roadmap, BioRAM). Očekuje se da će daljem razvoju u ovoj oblasti najviše doprineti združene aktivnosti i razmena znanja i iskustava između farmaceutskih kompanija i regulatornih agencija sa zajedničkim ciljem da se ubrza razvoj efikasnih i bezbednihlekova dizajniranih u skladu sa potrebama i očekivanjima pacijenata. | |
dc.publisher | Association of Chemists and Chemical Engineers of Serbia | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Hemijska industrija | |
dc.subject | Biowaiver | |
dc.subject | Clinical performance | |
dc.subject | Dissolution testing | |
dc.subject | In vitro-in vivo correlation | |
dc.subject | Physiologically based pharmacokinetic/biopharmaceutics modeling | |
dc.subject | izostavljanje in vivo stu-dija | |
dc.subject | klinički učinak | |
dc.subject | ispitivanje brzine ras-tvaranja | |
dc.subject | in vitro-in vivokorelacija | |
dc.subject | fiziolo-ški zasnovani farmakokinetički/biofarma-ceutski modeli | |
dc.title | Integrated biopharmaceutical approach in pharmaceutical development and drug characterization: General concept and application | |
dc.title | Integrisani biofarmaceutski pristup u razvoju i karakterizaciji lekova: opšti koncept i primena | |
dc.type | article | |
dc.rights.license | BY-NC-ND | |
dcterms.abstract | Цвијић, Сандра; Ибрић, Светлана; Паројчић, Јелена; Интегрисани биофармацеутски приступ у развоју и карактеризацији лекова: општи концепт и примена; Интегратед биопхармацеутицал аппроацх ин пхармацеутицал девелопмент анд друг цхарацтеризатион: Генерал цонцепт анд апплицатион; | |
dc.citation.volume | 74 | |
dc.citation.issue | 6 | |
dc.citation.spage | 389 | |
dc.citation.epage | 397 | |
dc.citation.rank | M23 | |
dc.identifier.wos | 000613646400004 | |
dc.identifier.doi | 10.2298/HEMIND210104002C | |
dc.identifier.scopus | 2-s2.0-85101154126 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs/bitstream/id/8619/Integrated_biopharmaceutica_approach_pub_2020.pdf | |
dc.type.version | publishedVersion |